Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
17 01 2019
Historique:
entrez: 20 1 2019
pubmed: 20 1 2019
medline: 11 2 2020
Statut: epublish

Résumé

The impact of lung cancer screening with low-dose chest CT (LDCT) on participants' anxiety levels and health-related quality of life (HRQoL) is an important consideration in the implementation of such programmes. We aimed to describe changes in anxiety and HRQoL in a high-risk Canadian cohort undergoing LDCT lung cancer screening. 2537 subjects who had 2% or greater lung cancer risk over 6 years using a risk prediction tool were recruited from eight centres across Canada in the Pan-Canadian Early Detection of Lung Cancer Study (2008-2010). We compared HRQoL and anxiety levels before and after screening of 1237 participants with LDCT (excluding a subset of 1300 participants who also underwent autofluorescence bronchoscopy screening), as well as after investigations performed because of a positive screening examination. The 12-item short-form Physical and Mental Component Scales (SF-12), EQ-5D-3L scores and State Trait Anxiety Inventory-State anxiety were used at each assessment. Overall, there were no clinically significant differences in HRQoL outcomes between baseline and each of the survey time points following initial screening. No mean change in anxiety in the overall cohort was noted following baseline LDCT, but more participants had clinically significant increase in anxiety versus decrease after baseline screening (increase >minimal clinically important difference (MCID) (n=180) vs decrease >MCID (n=50), p<0.001). This finding persisted but to a lesser degree at the 12 month time point (increase >MCID (n=146) vs decrease >MCID (n=87), p<0.001). CT screening for lung cancer has no major overall impact on HRQoL among participants, although a minority of participants (number-needed-to-harm=7 after baseline screening and 18 at 1 year) demonstrated clinically significant increased anxiety levels. NCT00751660; Results.

Identifiants

pubmed: 30659040
pii: bmjopen-2018-024719
doi: 10.1136/bmjopen-2018-024719
pmc: PMC6340441
doi:

Banques de données

ClinicalTrials.gov
['NCT00751660']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e024719

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Clin Lung Cancer. 2016 Sep;17(5):315-324
pubmed: 27130469
Thorax. 2016 Nov;71(11):996-1005
pubmed: 27471048
Med Decis Making. 2008 Nov-Dec;28(6):917-25
pubmed: 18725404
J Clin Oncol. 2016 Jun 1;34(16):1953-6
pubmed: 27091712
Cancer. 2014 Nov 1;120(21):3401-9
pubmed: 25065710
PLoS One. 2012;7(2):e31115
pubmed: 22328929
Eur J Cancer. 2001 Nov;37(17):2154-60
pubmed: 11677101
Lung Cancer. 2015 Jan;87(1):65-72
pubmed: 25433982
Eur Respir J. 2011 Jul;38(1):154-61
pubmed: 21148229
J Public Health Med. 1997 Jun;19(2):179-86
pubmed: 9243433
Respir Care. 2015 Jan;60(1):88-95
pubmed: 25336531
Qual Life Res. 2009 May;18(4):403-14
pubmed: 19242822
BMJ Open. 2012 Mar 01;2(2):e000663
pubmed: 22382119
Chest. 2016 Nov;150(5):1015-1022
pubmed: 27142184
Med Decis Making. 2015 Apr;35(3):371-87
pubmed: 25670839
JAMA. 2012 Jun 13;307(22):2418-29
pubmed: 22610500
J Natl Cancer Inst. 2004 Apr 7;96(7):529-38
pubmed: 15069115
Br J Cancer. 2010 Jan 5;102(1):27-34
pubmed: 19935789
J Neurosurg Spine. 2013 Feb;18(2):154-60
pubmed: 23176164
Lancet Oncol. 2017 Nov;18(11):1523-1531
pubmed: 29055736
Med Care. 2000 Jan;38(1):115-21
pubmed: 10630726
CMAJ. 2016 Apr 5;188(6):425-432
pubmed: 26952527
Lung Cancer. 2011 Sep;73(3):325-31
pubmed: 21324544
Value Health Reg Issues. 2016 May;9:57-62
pubmed: 27881260
J Natl Cancer Inst. 2004 Jul 21;96(14):1083-94
pubmed: 15265970
Med Care. 2007 Mar;45(3):259-63
pubmed: 17304084
N Engl J Med. 2013 Feb 21;368(8):728-36
pubmed: 23425165
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
Health Qual Life Outcomes. 2013 Apr 12;11:59
pubmed: 23587015
N Engl J Med. 2013 Sep 5;369(10):910-9
pubmed: 24004118
Radiology. 2011 Jan;258(1):243-53
pubmed: 21045183
J Thorac Oncol. 2014 Jul;9(7):927-34
pubmed: 24922011
J Thorac Dis. 2013 Oct;5 Suppl 5:S524-39
pubmed: 24163745
J Thorac Oncol. 2009 Jun;4(6):710-21
pubmed: 19404219
JAMA Intern Med. 2014 Feb 1;174(2):269-74
pubmed: 24322569
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Front Psychol. 2015 Aug 07;6:1171
pubmed: 26300841

Auteurs

Niloofar Taghizadeh (N)

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Alain Tremblay (A)

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Sonya Cressman (S)

Department of Integrative Oncology, The British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

Stuart Peacock (S)

Department of Integrative Oncology, The British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

Annette M McWilliams (AM)

Department of Respiratory Medicine, Fionna Stanley Hospital and University of Western Australia, Perth, Australia.

Paul MacEachern (P)

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Michael R Johnston (MR)

Department of Surgery, Beatrice Hunter Cancer Research Institute and Dalhousie University, Halifax, Canada.

John Goffin (J)

Department of Oncology, The Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada.

Glen Goss (G)

Department of Medicine, The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada.

Garth Nicholas (G)

Department of Medicine, The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada.

Simon Martel (S)

Department de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.

Francis Laberge (F)

Department de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada.

Rick Bhatia (R)

Department of Medicine, Memorial University, St John's, Newfoundland and Labrador, Canada.

Geoffrey Liu (G)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Heidi Schmidt (H)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Sukhinder Atkar-Khattra (S)

Department of Integrative Oncology, The British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

Ming-Sound Tsao (MS)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Martin C Tammemagi (MC)

Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada.

Stephen C Lam (SC)

Department of Integrative Oncology, The British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH